2020
Secondary prevention of cardiovascular disease in China
Lu J, Zhang L, Lu Y, Su M, Li X, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Li J, Zheng X. Secondary prevention of cardiovascular disease in China. Heart 2020, 106: 1349-1356. PMID: 31980439, DOI: 10.1136/heartjnl-2019-315884.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlcohol DrinkingCardiovascular DiseasesChinaFemaleHealthy LifestyleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsRisk AssessmentRisk Reduction BehaviorSecondary PreventionSex FactorsSmoking CessationTime FactorsTreatment OutcomeConceptsSecondary prevention drugsIschemic heart diseaseCardiovascular diseasePrevention drugsIschemic strokeSecondary preventionAntiplatelet drugsCardiac Events Million Persons ProjectHistory of IHDMillion Persons ProjectSecondary prevention therapiesPopulation subgroupsMultivariable mixed modelsPublic health programsCommunities of ChinaCurrent smokersCurrent useMedication usePrevention therapyMultivariable analysisChina PatientHeart diseaseCurrent drinkersHealth programsDrugs
2019
P834Secondary prevention medications of cardiovascular diseases in China: findings from China PEACE million persons project
Lu J, Zhang L, Lu Y, Su M, Li X, Li J, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Zheng X. P834Secondary prevention medications of cardiovascular diseases in China: findings from China PEACE million persons project. European Heart Journal 2019, 40: ehz747.0433. DOI: 10.1093/eurheartj/ehz747.0433.Peer-Reviewed Original ResearchSecondary prevention medicationsIschemic heart diseasePrevention medicationsAnti-platelet drugsCardiovascular diseaseMultivariable mixed modelsIschemic strokePopulation subgroupsCardiac Events Million Persons ProjectHistory of IHDPrognosis of CVDMillion Persons ProjectHealth behavior factorsSecondary prevention drugsCause of deathCurrent usePublic health programsPersons ProjectNational Health CommissionCurrent smokersSecondary preventionMedication useMultivariable analysisChina PatientPrevention drugsPrevalence, Awareness, and Treatment of Isolated Diastolic Hypertension: Insights From the China PEACE Million Persons Project
Mahajan S, Zhang D, He S, Lu Y, Gupta A, Spatz ES, Lu J, Huang C, Herrin J, Liu S, Yang J, Wu C, Cui J, Zhang Q, Li X, Nasir K, Zheng X, Krumholz HM, Li J, Dong Z, Jiang B, Zhang Y, Liu Y, Meng Y, Xi Y, Tian Y, Fu Y, Liu T, Yan S, Jin L, Wang J, Xu X, Xing X, Zhang L, Fang X, Xu Y, Xu C, Fan L, Qi M, Qi J, Li J, Liu Q, Feng Y, Wang J, Wen H, Xu J, He J, Jiang C, Yang C, Yu Y, Tashi Z, Hu Z, Zhang J, Li X, Ma S, Ma Y, Huang Y, Zhang Y, Shen J. Prevalence, Awareness, and Treatment of Isolated Diastolic Hypertension: Insights From the China PEACE Million Persons Project. Journal Of The American Heart Association 2019, 8: e012954. PMID: 31566101, PMCID: PMC6806046, DOI: 10.1161/jaha.119.012954.Peer-Reviewed Original ResearchConceptsMillion Persons ProjectPrior cardiovascular eventsBody mass indexAntihypertensive medicationsDiastolic hypertensionCardiovascular eventsDiabetes mellitusMass indexIsolated diastolic hypertensionDiastolic blood pressureSelf-reported diagnosisTreatment of peoplePersons ProjectBlood pressureTreatment patternsHypertensionLeast collegeHigher likelihoodMellitusMedicationsPrevalenceTreatmentDiagnosisSubstantial numberCurrent use
2014
Strategies to reduce hospital 30-day risk-standardized mortality rates for patients with acute myocardial infarction: a cross-sectional and longitudinal survey
Bradley EH, Sipsma H, Brewster AL, Krumholz HM, Curry L. Strategies to reduce hospital 30-day risk-standardized mortality rates for patients with acute myocardial infarction: a cross-sectional and longitudinal survey. BMC Cardiovascular Disorders 2014, 14: 126. PMID: 25252826, PMCID: PMC4182840, DOI: 10.1186/1471-2261-14-126.Peer-Reviewed Original ResearchMeSH KeywordsCooperative BehaviorCross-Sectional StudiesEmergency Medical ServicesEmergency Medical TechniciansHealth Care SurveysHospital MortalityHospitalsHumansInservice TrainingInterdisciplinary CommunicationLongitudinal StudiesMedical Order Entry SystemsMyocardial InfarctionOrganizational CulturePatient Care TeamQuality ImprovementQuality Indicators, Health CareTime FactorsUnited StatesConceptsAcute myocardial infarctionAMI mortality ratesPercentage of hospitalsMortality rateMyocardial infarctionAMI mortalityHospital AMI mortality ratesRisk-standardized mortality ratesEmergency medical services (EMS) providersHospital strategiesCross-sectional surveyPhysician order entryBackgroundSurvival ratesAMI careMedical service providersResultsBetween 2010HospitalU.S. hospitalsOrder entryRegular trainingInfarctionLongitudinal analysisHospital performanceMortalityCurrent use
2013
Quality collaboratives and campaigns to reduce readmissions: What strategies are hospitals using?
Bradley EH, Sipsma H, Curry L, Mehrotra D, Horwitz LI, Krumholz H. Quality collaboratives and campaigns to reduce readmissions: What strategies are hospitals using? Journal Of Hospital Medicine 2013, 8: 601-608. PMID: 24038927, PMCID: PMC4029612, DOI: 10.1002/jhm.2076.Peer-Reviewed Original ResearchMeSH KeywordsContinuity of Patient CareCooperative BehaviorCross-Sectional StudiesHealth Care SurveysHealth Plan ImplementationHumansInformation DisseminationInternetLogistic ModelsMedication ReconciliationMultivariate AnalysisPatient DischargePatient ReadmissionQuality Assurance, Health CareQuality Indicators, Health CareUnited StatesConceptsQuality collaborativesCardiac rehabilitation servicesMultivariable logistic regressionSkilled nursing facilitiesHospital readmissionMedication reconciliationTreating physicianPatient dischargePatient referralOutpatient physiciansMultivariable modelNursing facilitiesStandard frequency analysisHospitalRehabilitation servicesWeb-based surveyReadmissionLogistic regressionQuality InitiativeHospital strategiesPhysiciansCurrent useCollaborativesPatientsSTAAR
2011
Use of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials